DE69738138D1 - Induktion von immunologischer Toleranz gegen einen therapeutischen Antikörper durch Varianten des therapeutischen Antikörpers - Google Patents

Induktion von immunologischer Toleranz gegen einen therapeutischen Antikörper durch Varianten des therapeutischen Antikörpers

Info

Publication number
DE69738138D1
DE69738138D1 DE69738138T DE69738138T DE69738138D1 DE 69738138 D1 DE69738138 D1 DE 69738138D1 DE 69738138 T DE69738138 T DE 69738138T DE 69738138 T DE69738138 T DE 69738138T DE 69738138 D1 DE69738138 D1 DE 69738138D1
Authority
DE
Germany
Prior art keywords
therapeutic antibody
antibody
immunological tolerance
variants
induction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69738138T
Other languages
English (en)
Other versions
DE69738138T2 (de
Inventor
Herman Waldmann
Lisa Kim Gilliland
Masahide Tone
Mark Raymond Frewin
Louise Walsh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford University Innovation Ltd
Original Assignee
Oxford University Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford University Innovation Ltd filed Critical Oxford University Innovation Ltd
Publication of DE69738138D1 publication Critical patent/DE69738138D1/de
Application granted granted Critical
Publication of DE69738138T2 publication Critical patent/DE69738138T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
DE69738138T 1996-02-20 1997-02-20 Induktion von immunologischer Toleranz gegen einen therapeutischen Antikörper durch Varianten des therapeutischen Antikörpers Expired - Lifetime DE69738138T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9603507 1996-02-20
GBGB9603507.6A GB9603507D0 (en) 1996-02-20 1996-02-20 Antibody variants
PCT/GB1997/000472 WO1997031024A1 (en) 1996-02-20 1997-02-20 Antibody variants

Publications (2)

Publication Number Publication Date
DE69738138D1 true DE69738138D1 (de) 2007-10-25
DE69738138T2 DE69738138T2 (de) 2008-06-05

Family

ID=10789047

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69738138T Expired - Lifetime DE69738138T2 (de) 1996-02-20 1997-02-20 Induktion von immunologischer Toleranz gegen einen therapeutischen Antikörper durch Varianten des therapeutischen Antikörpers

Country Status (11)

Country Link
US (2) US20020048578A1 (de)
EP (1) EP0970127B1 (de)
JP (1) JP4574750B2 (de)
AT (1) ATE373016T1 (de)
AU (1) AU723366B2 (de)
CA (1) CA2246715C (de)
DE (1) DE69738138T2 (de)
ES (1) ES2294793T3 (de)
GB (1) GB9603507D0 (de)
NZ (1) NZ331299A (de)
WO (1) WO1997031024A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69621940T2 (de) * 1995-08-18 2003-01-16 Morphosys Ag Protein-/(poly)peptidbibliotheken
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
PT1135498E (pt) 1998-11-18 2008-04-30 Genentech Inc Variantes de anticorpos com maior afinidade de ligação em comparação com os anticorpos parentais
US7465790B2 (en) 2000-10-09 2008-12-16 Isis Innovation, Inc. Therapeutic antibodies
ES2368387T5 (es) * 2000-10-09 2019-03-07 Cytomx Therapeutics Inc Anticuerpos terapéuticos y que inducen tolerancia
US20040109855A1 (en) * 2002-07-23 2004-06-10 Herman Waldmann Therapeutic antibodies with reduced side effect
CA2520830A1 (en) * 2003-03-31 2004-10-14 Kirin Beer Kabushiki Kaisha Method for inducing differentiation and/or proliferating regulatory t cells using anti-cd52 antibodies and pharmaceutical composition therefor
NZ550815A (en) * 2004-05-19 2009-04-30 Immunocore Ltd Method of improving T cell receptors
EP1863531A1 (de) * 2005-03-19 2007-12-12 Medical Research Council Verbesserungen der behandlung und prävention von virusinfektionen
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
WO2008144484A1 (en) * 2007-05-16 2008-11-27 Sinomab Bioscience Limited Functional humanization of complementarity determining regions (cdrs)
CA3128656A1 (en) 2007-08-22 2009-02-26 The Regents Of The University Of California Activatable binding polypeptides and methods of identification and use thereof
CA2749339A1 (en) 2009-01-12 2010-07-15 Cytomx Therapeutics, Llc Modified antibody compositions, methods of making and using thereof
CA2753294A1 (en) 2009-02-23 2010-08-26 Cytomx Therapeutics, Inc. Proproteins and methods of use thereof
NZ621170A (en) 2009-05-13 2015-08-28 Genzyme Corp Anti-human cd52 immunoglobulins
RU2569187C2 (ru) 2009-05-29 2015-11-20 МорфоСис АГ Коллекция и способы ее применения
MX353795B (es) 2010-11-19 2018-01-30 Morphosys Ag Coleccion y metodos para su uso.
GB201109238D0 (en) * 2011-06-01 2011-07-13 Antitope Ltd Antibodies
WO2013152011A1 (en) * 2012-04-02 2013-10-10 Ab Biosciences, Inc. Novel human control antibodies and uses therefor
MX2014013041A (es) 2012-04-27 2015-03-19 Cytomx Therapeutics Inc Anticuerpos activables que se ligan al receptor del factor de crecimiento epidermico y metodos de uso de los mismos.
MX2015014181A (es) 2013-04-09 2016-05-24 Boston Biomedical Inc 2-acetilnafto [2,3-b]furano -4,9-diona para uso en el tratamiento del cáncer.
US9540440B2 (en) 2013-10-30 2017-01-10 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
WO2015089283A1 (en) 2013-12-11 2015-06-18 Cytomx Therapeutics, Inc. Antibodies that bind activatable antibodies and methods of use thereof
US20160120158A1 (en) * 2014-11-03 2016-05-05 The Johns Hopkins University Compositions and methods for the study and treatment of acute kidney injury
JP2018521979A (ja) 2015-06-03 2018-08-09 ボストン バイオメディカル， インコーポレイテッド 癌の治療に使用するための癌幹細胞性阻害剤および免疫療法剤を含む組成物
WO2018102427A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
JP2020520923A (ja) 2017-05-17 2020-07-16 ボストン バイオメディカル， インコーポレイテッド がんを処置するための方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5846534A (en) * 1988-02-12 1998-12-08 British Technology Group Limited Antibodies to the antigen campath-1
EP0328404B1 (de) * 1988-02-12 1993-09-29 Btg International Limited Modifizierte Antikörper
US5858725A (en) * 1990-10-10 1999-01-12 Glaxo Wellcome Inc. Preparation of chimaeric antibodies using the recombinant PCR strategy
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
DK0610447T3 (da) * 1991-10-15 1999-08-23 Btg Int Ltd CDw52-specifikt antistof til behandling af T-cellemedieret inflammation af leddene
GB9125768D0 (en) * 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method

Also Published As

Publication number Publication date
CA2246715A1 (en) 1997-08-28
GB9603507D0 (en) 1996-04-17
CA2246715C (en) 2008-08-05
EP0970127B1 (de) 2007-09-12
AU723366B2 (en) 2000-08-24
EP0970127A1 (de) 2000-01-12
WO1997031024A1 (en) 1997-08-28
JP4574750B2 (ja) 2010-11-04
ES2294793T3 (es) 2008-04-01
US20020048578A1 (en) 2002-04-25
AU1885197A (en) 1997-09-10
ATE373016T1 (de) 2007-09-15
NZ331299A (en) 2000-05-26
US8440190B2 (en) 2013-05-14
JP2000506723A (ja) 2000-06-06
DE69738138T2 (de) 2008-06-05
US20060018898A1 (en) 2006-01-26

Similar Documents

Publication Publication Date Title
DE69738138D1 (de) Induktion von immunologischer Toleranz gegen einen therapeutischen Antikörper durch Varianten des therapeutischen Antikörpers
EE200700052A (et) Antikeha he v?i mitme apo-lipoproteiin B fragmendi vastu
AT500379B8 (de) Tau-proteine
DE69433406T2 (de) Antikörper gegen cd40
ATE513563T1 (de) Therapeutische und toleranz-induzierende antikörper
ATE470676T1 (de) Anti-vegf-2 antikörper
EA200501286A1 (ru) МОЛЕКУЛЫ АНТИТЕЛ СО СПЕЦИФИЧНОСТЬЮ К ЧЕЛОВЕЧЕСКОМУ IL-1β
ATE178907T1 (de) Rezeptorbindende region des diphtherietoxius
EP3569610A3 (de) Moleküle mit verlängerter halbwertzeit, zusammensetzungen und verwendungen dafür
CY1109817T1 (el) Ολιγο-βητα-(1,3)-γλυκανη και μονοκλωνικα αντισωματα εναντιον καρκινου
DE60238533D1 (de) Nicht-depletierender Antikörper TRX-1 gegen CD4 und dessen Verwendungen
DE69530844D1 (de) Verfahren und substanzen gegen protozoen
DE69638024D1 (de) Melanoma antigene p15 und deren anwendung in diagnostischen und therapeutischen verfahren
PT812206E (pt) Proteina de ligacao a cd40 para estimulacao de uma resposta imunitaria
DE69426767D1 (de) Anti idiotypische Antikörper gegen Gonococcen und diese verwendende Verfahren und Zusammensetzungen.
EA200200974A1 (ru) Моноклональные антитела к рецептору лпнп человека, их получение и применение
DE69636527D1 (de) Antigenes protein aus malassezia
ATE136469T1 (de) Neue verwendung eines monoklonalen antikörpers
ATE108832T1 (de) Verwendung von monoklonalen antikörpern gegen b2- mikroglobulin.
DK0858465T3 (da) Protein med antitumorvirkning.
RU96123360A (ru) Способ лечения сепсиса у новорожденных

Legal Events

Date Code Title Description
8364 No opposition during term of opposition